Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma · Sponsor: AstraZeneca
About this study
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (160)
| Research Site | Los Angeles, California, United States | — |
| Research Site | Orange, California, United States | — |
| Research Site | San Francisco, California, United States | — |
| Research Site | Washington D.C., District of Columbia, United States | — |
| Research Site | Fort Myers, Florida, United States | — |
| Research Site | Jacksonville, Florida, United States | — |
| Research Site | Westwood, Kansas, United States | — |
| Research Site | Baltimore, Maryland, United States | — |
| Research Site | Ann Arbor, Michigan, United States | — |
| Research Site | Rochester, Minnesota, United States | — |
| Research Site | New York, New York, United States | — |
| Research Site | Charlotte, North Carolina, United States | — |
+ 148 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03298451